The neoantigen cancer vaccine market is expected to grow from US$ 220 million in 2022 to US$ 4,423 million by 2032, at a CAGR of 35% during the forecast period 2023-2032.
Neoantigen is a protein that develops on malignant cells as a result of tumor DNA alterations. As a result, they are being exploited in creating vaccines and immunotherapies against cancer cells. Neoantigen-specific T cell receptors (TCRs) recognize neoantigens in the body. Because they can be recognized as non-self/foreign and germline by the host's immune system, neoantigen-based vaccinations, and target therapies have demonstrated promising effects in several clinical trials.
Neoantigens are extremely important in cancer immunoediting. It is a strategy used to establish the immune system's dual functions in tumor progression. Several studies have suggested that neoantigen immunotherapy can help restrict tumor expansion, facilitate cellular change, and share tumor immunogenicity. Additionally, neoantigens can be classified as personalized neoantigens or shared neoantigens. Shared neoantigens do not exist in the individualized genome, but personalized neoantigens are directed toward unique individuals. Predicting the number of neoantigens present requires using well-thought-out verified algorithms to select more trustworthy neoepitopes. Obtaining tumorous tissues from the patient and then identifying mutant genes of the tumor is the technique for developing a neoantigen cancer vaccine. Following that, an RNA/DNA sequence test is performed to determine relevant mutant antigens. Finally, these altered antigens are developed into vaccinations.
This study delivers a comprehensive analysis of the type, technology, and region. The type segment includes tumor cell, nucleic acid, synthetic long peptide, and dendritic acid. The nucleic acid segment holds the largest market share in 2022. The two major types of nucleic acids are deoxyribonucleic acid and ribonucleic acid. DNA and RNA are responsible for the transmission of certain features from generation to generation. The technology segment includes whole genome sequencing, RNA sequencing, and HLA typing. The RNA sequencing segment held the largest market share in 2022. RNA-seq (RNA-sequencing) is a technique that uses next-generation sequencing (NGS) to investigate the quantity and sequences of RNA in a sample. It examines the transcriptome to determine which genes encoded in our DNA are activated or deactivated and to what extent.
The market has been divided into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America holds the largest market share, Because of the expanding number of cancer cases in the region, as well as the growing demand for the development of sophisticated treatment procedures. BioNTech S.E. has created and introduced the IVAC platform, which aids in the manufacture of customized neoantigen vaccines. Furthermore, Genocea Biosciences also created the ATLAS platform for the creation of neoantigen vaccines. It treats melanoma, carcinoma, and lung malignancies using an ex-vivo approach.
Some of the notable players in the market are Roche, Medimmune, Moderna Therapeutics/Merck, Advaxis, Agenus, Genocea, Gritstone Oncology, Neon Therapeutics, Nouscom, OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, Vaccibody, Brightpath Biotherapeutics, Geneos Therapeutics, and others.
Report Description:
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis by Type
4.3.2. Market Attractiveness Analysis by Technology
4.3.3. Market Attractiveness Analysis by Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. Rising cancer cases
5.3. Restraints
5.3.1. High cost
5.4. Opportunities
5.4.1. Rising healthcare development
5.5. Challenges
5.5.1. Lack of adaptability
6. Global Neoantigen Cancer Vaccine Market Analysis and Forecast, By Type
6.1. Segment Overview
6.2. Tumor Cell
6.3. Nucleic Acid
6.4. Synthetic Long Peptide
6.5. Dendritic Acid
7. Global Neoantigen Cancer Vaccine Market Analysis and Forecast, By Technology
7.1. Segment Overview
7.2. Whole Genome Sequencing
7.3. RNA Sequencing
7.4. HLA Typing
8. Global Neoantigen Cancer Vaccine Market Analysis and Forecast, By Regional Analysis
8.1. Segment Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.5. South America
8.5.1. Brazil
8.6. Middle East and Africa
8.6.1. UAE
8.6.2. South Africa
9. Global Neoantigen Cancer Vaccine Market-Competitive Landscape
9.1. Overview
9.2. Market Share of Key Players in Global Neoantigen Cancer Vaccine Market
9.2.1. Global Company Market Share
9.2.2. North America Company Market Share
9.2.3. Europe Company Market Share
9.2.4. APAC Company Market Share
9.3. Competitive Situations and Trends
9.3.1. Product Launches and Developments
9.3.2. Partnerships, Collaborations, and Agreements
9.3.3. Mergers & Acquisitions
9.3.4. Expansions
10. Company Profiles
10.1. Roche
10.1.1. Business Overview
10.1.2. Company Snapshot
10.1.3. Company Market Share Analysis
10.1.4. Company Product Portfolio
10.1.5. Recent Developments
10.1.6. SWOT Analysis
10.2. Medimmune
10.2.1. Business Overview
10.2.2. Company Snapshot
10.2.3. Company Market Share Analysis
10.2.4. Company Product Portfolio
10.2.5. Recent Developments
10.2.6. SWOT Analysis
10.3. Moderna Therapeutics/Merck
10.3.1. Business Overview
10.3.2. Company Snapshot
10.3.3. Company Market Share Analysis
10.3.4. Company Product Portfolio
10.3.5. Recent Developments
10.3.6. SWOT Analysis
10.4. Advaxis
10.4.1. Business Overview
10.4.2. Company Snapshot
10.4.3. Company Market Share Analysis
10.4.4. Company Product Portfolio
10.4.5. Recent Developments
10.4.6. SWOT Analysis
10.5. Agenus
10.5.1. Business Overview
10.5.2. Company Snapshot
10.5.3. Company Market Share Analysis
10.5.4. Company Product Portfolio
10.5.5. Recent Developments
10.5.6. SWOT Analysis
10.6. Genocea
10.6.1. Business Overview
10.6.2. Company Snapshot
10.6.3. Company Market Share Analysis
10.6.4. Company Product Portfolio
10.6.5. Recent Developments
10.6.6. SWOT Analysis
10.7. Gritstone Oncology
10.7.1. Business Overview
10.7.2. Company Snapshot
10.7.3. Company Market Share Analysis
10.7.4. Company Product Portfolio
10.7.5. Recent Developments
10.7.6. SWOT Analysis
10.8. Neon Therapeutics
10.8.1. Business Overview
10.8.2. Company Snapshot
10.8.3. Company Market Share Analysis
10.8.4. Company Product Portfolio
10.8.5. Recent Developments
10.8.6. SWOT Analysis
10.9. Nouscom
10.9.1. Business Overview
10.9.2. Company Snapshot
10.9.3. Company Market Share Analysis
10.9.4. Company Product Portfolio
10.9.5. Recent Developments
10.9.6. SWOT Analysis
10.10. OSE Immunotherapeutics
10.10.1. Business Overview
10.10.2. Company Snapshot
10.10.3. Company Market Share Analysis
10.10.4. Company Product Portfolio
10.10.5. Recent Developments
10.10.6. SWOT Analysis
10.11. Immunovative Therapeutics
10.11.1. Business Overview
10.11.2. Company Snapshot
10.11.3. Company Market Share Analysis
10.11.4. Company Product Portfolio
10.11.5. Recent Developments
10.11.6. SWOT Analysis
10.12. Medigene
10.12.1. Business Overview
10.12.2. Company Snapshot
10.12.3. Company Market Share Analysis
10.12.4. Company Product Portfolio
10.12.5. Recent Developments
10.12.6. SWOT Analysis
10.13. Vaccibody
10.13.1. Business Overview
10.13.2. Company Snapshot
10.13.3. Company Market Share Analysis
10.13.4. Company Product Portfolio
10.13.5. Recent Developments
10.13.6. SWOT Analysis
10.14. Brightpath Biotherapeutics
10.14.1. Business Overview
10.14.2. Company Snapshot
10.14.3. Company Market Share Analysis
10.14.4. Company Product Portfolio
10.14.5. Recent Developments
10.14.6. SWOT Analysis
10.15. Geneos Therapeutics
10.15.1. Business Overview
10.15.2. Company Snapshot
10.15.3. Company Market Share Analysis
10.15.4. Company Product Portfolio
10.15.5. Recent Developments
10.15.6. SWOT Analysis
List of Table
1. Global Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
2. Global Tumor Cell, Neoantigen Cancer Vaccine Market, By Region, 2019-2032 (USD Million)
3. Global Nucleic Acid, Neoantigen Cancer Vaccine Market, By Region, 2019-2032 (USD Million)
4. Global Synthetic Long Peptide, Neoantigen Cancer Vaccine Market, By Region, 2019-2032 (USD Million)
5. Global Dendritic Acid, Neoantigen Cancer Vaccine Market, By Region, 2019-2032 (USD Million)
6. Global Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
7. Global Whole Genome Sequencing, Neoantigen Cancer Vaccine Market, By Region, 2019-2032 (USD Million)
8. Global RNA Sequencing, Neoantigen Cancer Vaccine Market, By Region, 2019-2032 (USD Million)
9. Global HLA Typing, Neoantigen Cancer Vaccine Market, By Region, 2019-2032 (USD Million)
10. North America Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
11. North America Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
12. U.S. Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
13. U.S. Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
14. Canada Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
15. Canada Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
16. Mexico Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
17. Mexico Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
18. Europe Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
19. Europe Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
20. Germany Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
21. Germany Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
22. France Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
23. France Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
24. U.K. Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
25. U.K. Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
26. Italy Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
27. Italy Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
28. Spain Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
29. Spain Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
30. Asia Pacific Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
31. Asia Pacific Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
32. Japan Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
33. Japan Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
34. China Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
35. China Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
36. India Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
37. India Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
38. South America Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
39. South America Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
40. Brazil Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
41. Brazil Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
42. Middle East and Africa Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
43. Middle East and Africa Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
44. UAE Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
45. UAE Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
46. South Africa Neoantigen Cancer Vaccine Market, By Type, 2019-2032 (USD Million)
47. South Africa Neoantigen Cancer Vaccine Market, By Technology, 2019-2032 (USD Million)
List of Figures
1. Global Neoantigen Cancer Vaccine Market Segmentation
2. Global Neoantigen Cancer Vaccine Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Neoantigen Cancer Vaccine Market Attractiveness Analysis by Type
9. Global Neoantigen Cancer Vaccine Market Attractiveness Analysis by Technology
10. Global Neoantigen Cancer Vaccine Market Attractiveness Analysis by Region
11. Global Neoantigen Cancer Vaccine Market: Dynamics
12. Global Neoantigen Cancer Vaccine Market Share by Type (2023 & 2032)
13. Global Neoantigen Cancer Vaccine Market Share by Technology (2023 & 2032)
14. Global Neoantigen Cancer Vaccine Market Share by Regions (2023 & 2032)
15. Global Neoantigen Cancer Vaccine Market Share by Company (2022)
Market research is a method of gathering, assessing and deducing data & information about a particular market. Market research is very crucial in these days. The techniques analyze about how a product/service can be offered to the market to its end-customers, observe the impact of that product/service based on the past customer experiences, and cater their needs and demands. Owing to the successful business ventures, accurate, relevant and thorough information is the base for all the organizations because market research report/study offers specific market related data & information about the industry growth prospects, perspective of the existing customers, and the overall market scenario prevailed in past, ongoing present and developing future. It allows the stakeholders and investors to determine the probability of a business before committing substantial resources to the venture. Market research helps in solving the marketing issues challenges that a business will most likely face.
Market research is valuable because of the following reasons:
Our research report features both the aspects; qualitative and quantitative. Qualitative part provides insights about the market driving forces, potential opportunities, customer’s demands and requirement which in turn help the companies to come up with new strategies in order to survive in the long run competition. The quantitative segment offers the most credible information related to the industry. Based on the data gathering, we use to derive the market size and estimate their future growth prospects on the basis of global, region and country.
Our market research process involves with the four specific stages.
Data Collection: This stage of the market research process involves with the gathering and collecting of the market/industry related data from the sources. There are basically two types of research methods:
Data Synthesis: This stage includes the evaluation and assessment of all the data acquired from the primary and secondary research. It likewise includes in evaluating the information for any disparity watched while information gathering identified with the market. The data & information is gathered with consideration to the heterogeneity of sources. Scientific and statistical methods are implemented for synthesizing dissimilar information sets and provide the relevant data which is fundamental for formulating strategies. Our organization has broad involvement with information amalgamation where the information goes through different stages:
Market Formulation & Deduction: The last stage includes assigning the data & information in a suitable way in order to derive market size. Analyst reviews and domain based opinions based on holistic approach of market estimation combined with industry investigation additionally features a crucial role in this stage.
This stage includes with the finalization of the market size and numbers that we have gathered from primary and secondary research. With the data & information addition, we ensure that there is no gap in the market information. Market trend analysis is finished by our analysts by utilizing data extrapolation procedures, which give the most ideal figures to the market.
Data Validation: Validation is the most crucial step in the process. Validation & re-validation through scientifically designed technique and process that helps us finalize data-points to be used for final calculations. This stage also involves with the data triangulation process. Data triangulation generally implicates the cross validation and matching the data which has been collected from primary and secondary research methods.
Free Customization
Countries can be added on demand
Free yearly update on purchase of Multi/Corporate User License
Companies served till date
We serve our customers 24x7 for 365 days through calls, emails and live chat options.
Huge database of exceptional market reports bringing market intelligence to your fingertips.
SSL enabled, we offer you various secured payment options for risk free purchase.